Tango Therapeutics

TNGX · NASDAQ

$25.25+$1.72 (+7.31%)TodayMarket closed · Oct 20, 7:57 PM ET

Prev close $23.53

Latest news

NewsSep 9, 10:04 AM ETAvi Kapoor
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday
Press releaseAug 11, 11:00 AM ETGlobe Newswire
NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float
Press releaseAug 11, 7:00 AM ETGlobe Newswire
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Press releaseAug 6, 6:24 PM ETGlobe Newswire
Tango Therapeutics Announces Executive Chair Transition
Press releaseJun 22, 4:05 PM ETGlobe Newswire
Tango Therapeutics Appoints Robert Azelby to Board of Directors
NewsJun 8, 9:41 PM ETShivdeep Dhaliwal
Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are On Investors' Radars Today
NewsJun 8, 12:11 PM ETAvi Kapoor
Crude Oil Gains Over 1%; Motorcar Parts Of America Shares Surge After Q4 Earnings
NewsJun 8, 7:46 AM ETVandana Singh
Why Is Tango Therapeutics Stock Soaring Monday?
Press releaseJun 8, 6:59 AM ETGlobe Newswire
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
NewsMay 15, 12:17 PM ETAvi Kapoor
Crude Oil Surges 3%; RBC Bearings Earnings Top Views
NewsMay 15, 8:02 AM ETAvi Kapoor
DeFi Technologies, Babcock & Wilcox And Other Big Stocks Moving Lower In Friday's Pre-Market Session
NewsMay 15, 5:38 AM ETAvi Kapoor
Why Figma Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Press releaseMay 13, 4:07 PM ETGlobe Newswire
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
NewsApr 15, 9:16 AM ET
Tango Therapeutics Appoints Matthew Gall CFO, Effective Immediately
Press releaseApr 15, 9:05 AM ETGlobe Newswire
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
Press releaseMar 19, 11:00 AM ETGlobe Newswire
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
NewsMar 6, 8:00 AM ET
4 Analysts Have This To Say About Tango Therapeutics
NewsMar 5, 12:05 PM ET
12 Health Care Stocks Moving In Thursday's Intraday Session
NewsMar 5, 7:02 AM ET
Tango Therapeutics Q4 Earnings Summary & Key Takeaways
Press releaseMar 5, 7:01 AM ETGlobe Newswire
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
Press releaseMar 5, 7:00 AM ETGlobe Newswire
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
NewsMar 4, 12:02 PM ET
Examining the Future: Tango Therapeutics's Earnings Outlook
NewsFeb 6, 3:01 PM ET
Expert Outlook: Tango Therapeutics Through The Eyes Of 4 Analysts
Press releaseDec 12, 10:47 AM ETPRNewswire
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance
NewsNov 3, 2:02 PM ET
A Peek at Tango Therapeutics's Future Earnings
NewsOct 23, 11:17 AM ETVandana Singh
Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement
NewsAug 5, 4:32 AM ET
Earnings Scheduled For August 5, 2025
NewsMay 9, 4:03 PM ET
Insights into Tango Therapeutics's Upcoming Earnings
NewsDec 5, 10:01 AM ET
Unveiling 5 Analyst Insights On Tango Therapeutics
Press releaseDec 3, 7:00 AM ETBusiness Wire
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseNov 27, 7:00 AM ETBusiness Wire
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
NewsNov 11, 1:00 PM ET
The Analyst Landscape: 5 Takes On Tango Therapeutics
NewsNov 6, 11:34 AM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsNov 6, 7:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseNov 6, 7:05 AM ETBusiness Wire
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Press releaseNov 6, 7:00 AM ETBusiness Wire
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
NewsSep 10, 9:00 AM ET
Analyst Scoreboard: 4 Ratings For Tango Therapeutics
Press releaseAug 28, 7:00 AM ETBusiness Wire
Tango Therapeutics to Participate in Upcoming Investor Conferences
NewsAug 8, 10:00 AM ET
Analyst Expectations For Tango Therapeutics's Future
Press releaseAug 7, 7:00 AM ETBusiness Wire
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
NewsJul 9, 9:00 AM ET
Expert Outlook: Tango Therapeutics Through The Eyes Of 6 Analysts

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday

NeOnc Approaches a Major Biotech Inflection Point as tomorrow’s Brain-Cancer Data is set to Collide with a Tight Float

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Tango Therapeutics Announces Executive Chair Transition

Tango Therapeutics Appoints Robert Azelby to Board of Directors

Apple, SUNation Energy, Tango Therapeutics, Applied Digital And Cerebras Systems: Why These 5 Stocks Are On Investors' Radars Today

Crude Oil Gains Over 1%; Motorcar Parts Of America Shares Surge After Q4 Earnings

Why Is Tango Therapeutics Stock Soaring Monday?

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

Crude Oil Surges 3%; RBC Bearings Earnings Top Views

DeFi Technologies, Babcock & Wilcox And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Why Figma Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

Tango Therapeutics Appoints Matthew Gall CFO, Effective Immediately

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

4 Analysts Have This To Say About Tango Therapeutics

12 Health Care Stocks Moving In Thursday's Intraday Session

Tango Therapeutics Q4 Earnings Summary & Key Takeaways

Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Examining the Future: Tango Therapeutics's Earnings Outlook

Expert Outlook: Tango Therapeutics Through The Eyes Of 4 Analysts

Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance

A Peek at Tango Therapeutics's Future Earnings

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement

Earnings Scheduled For August 5, 2025

Insights into Tango Therapeutics's Upcoming Earnings

Unveiling 5 Analyst Insights On Tango Therapeutics

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

The Analyst Landscape: 5 Takes On Tango Therapeutics

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program

Analyst Scoreboard: 4 Ratings For Tango Therapeutics

Tango Therapeutics to Participate in Upcoming Investor Conferences

Analyst Expectations For Tango Therapeutics's Future

Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Expert Outlook: Tango Therapeutics Through The Eyes Of 6 Analysts